Advertisement
Screener

MEDICINOVA, INC. (MNOV) Material Contracts

MEDICINOVA, INC. Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

  • 2025-08-01: Form 8-K; Exhibit 10.1; Description Standby Equity Purchase Agreement dated as of July 30, 2025 by and between the Company and YA II PN Ltd..
  • 2024-08-08: Form 10-Q; Exhibit 10.1; Description Consulting Agreement, dated April 2, 2024, by and between the Registrant and Geoffrey O'Brien.
  • 2023-03-28: Form 10-K/A; Exhibit 10.27; Description Comprehensive Termination Agreement, by and between Medicinova, Inc. and Kissei Pharmaceutical Co., Ltd..
  • 2023-02-16: Form 10-K; Exhibit 10.27; Description Comprehensive Termination Agreement, by and between Medicinova, Inc. and Kissei Pharmaceutical Co., Ltd..
FiledFormExhibitDescription
2025-08-018-K10.1Standby Equity Purchase Agreement dated as of July 30, 2025 by and between the Company and YA II PN Ltd.
2024-08-0810-Q10.1Consulting Agreement, dated April 2, 2024, by and between the Registrant and Geoffrey O'Brien
2023-03-2810-K/A10.27Comprehensive Termination Agreement, by and between Medicinova, Inc. and Kissei Pharmaceutical Co., Ltd.
2023-02-1610-K10.27Comprehensive Termination Agreement, by and between Medicinova, Inc. and Kissei Pharmaceutical Co., Ltd.
2021-01-128-K10.2Shareholder Rights Agreement, dated January 11, 2021, between the Company and the Investor.
2021-01-128-K10.1Securities Purchase Agreement, dated January 11, 2021, between the Company and the Investor.
2019-08-238-K10.1At Market Issuance Sales Agreement, dated August 23, 2019, by and between MediciNova, Inc. and B. Riley FBR, Inc.
2017-09-078-K10.1Sublease, by and between the Company and Cardinal Health 127 Inc., dated August 31, 2017.
2017-07-2610-Q10.1Amended and Restated 2013 Equity Incentive Plan of the Registrant.
2016-09-168-K10.1Amendment No. 1 to At-the-Market Issuance Sales Agreement, dated September 16, 2016, by and among MediciNova, Inc., MLV & Co. LLC and FBR Capital Markets & Co.
2016-03-318-K10.1Services Agreement, effective March 31, 2016, by and between MediciNova, Inc. and Signature Analytics San Diego LLC.
2015-05-228-K10.1At-the-Market Issuance Sales Agreement, dated May 22, 2015, by and between MediciNova, Inc. and MLV & Co. LLC.
2015-04-038-K10.1Engagement Agreement, effective April 3, 2015, by and between MediciNova, Inc. and van den Boom & Associates, LLC.
2014-08-1310-Q10.5Severance Protection Agreement, dated July 14, 2014, by and between MediciNova, Inc. and Geoffrey O’Brien.
2014-08-1310-Q10.4Severance Protection Agreement, dated July 14, 2014, by and between MediciNova, Inc. and Dr. Kazuko Matsuda.
2014-08-1310-Q10.3Severance Protection Agreement, dated July 14, 2014, by and between MediciNova, Inc. and Masatsune Okajima.
2014-08-1310-Q10.2Severance Protection Agreement, dated July 14, 2014, by and between MediciNova, Inc. and Dr. Yuichi Iwaki.
2014-07-118-K10.1Form of Severance Protection Agreement.
2014-04-098-K10.1Engagement Agreement, effective April 8, 2014, by and between MediciNova, Inc. and van den Boom & Associates, LLC.
2014-03-2710-K10.232013 Equity Incentive Plan of the Registrant.
2013-11-0710-Q10.3Form of Notice of Stock Option Grant and Stock Option Agreement for awards pursuant to the 2013 Equity Incentive Plan.
2013-10-168-K10.1Equity Distribution Agreement, dated October 16, 2013, by and between MediciNova, Inc. and Macquarie Capital (USA) Inc.
2013-09-268-K10.1Severance Agreement and Release, dated as of September 25, 2013, by and between MediciNova, Inc. and Kirk Johnson, Ph.D.
2013-05-108-K10.1Securities Purchase Agreement, dated as of May 9, 2013, by and between the Company and the investors named therein.
2013-04-188-K10.1Equity Distribution Agreement, dated April 17, 2013, by and between MediciNova, Inc. and Macquarie Capital (USA) Inc.
2013-03-2810-K10.3Form of Indemnification Agreement between the Registrant and its officers and directors.
2013-03-018-K10.1Sublease Agreement between the Company and Denali Advisors LLC dated February 27, 2013.
2012-08-228-K10.1WARRANT
2012-08-218-K10.1COMMON STOCK PURCHASE AGREEMENT
2012-03-2910-K10.2AMENDED AND RESTATED 2004 STOCK INCENTIVE PLAN OF THE REGISTRANT
2012-03-228-K10.1SIXTH AMENDMENT TO LEASE AGREEMENT
2011-09-278-K10.1STOCK PURCHASE AGREEMENT
2011-09-088-K10.1CONFIDENTIAL CONSULTING AGREEMENT
2011-08-1510-Q10.44JOINT VENTURE AGREEMENT
2011-07-128-K10.1FIFTH AMENDMENT TO LEASE AGREEMENT
2011-05-1610-Q10.42PAY-OFF LETTER DATED MARCH 31, 2011
2011-05-068-K10.1AT-THE-MARKET ISSUANCE SALES AGREEMENT
2011-02-038-K10.1SEPARATION AGREEMENT
2011-01-048-K10.2FORM OF AMENDMENT TO SEVERANCE PROTECTION AGREEMENT
2011-01-048-K10.1FORM OF AMENDMENT TO EMPLOYMENT AGREEMENT
2010-06-168-K10.1EXECUTIVE EMPLOYMENT AGREEMENT
2010-05-148-K10.1LOAN AND SECURITY AGREEMENT DATED MAY 10, 2010
2010-02-018-K10.1EXECUTIVE EMPLOYMENT AGREEMENT
2009-09-258-K10.1FIRST AMENDMENT TO CONSULTING AGREEMENT
2009-07-168-K10.1SEPERATION AGREEMENT AND RELEASE
2009-07-028-K10.1SEPARATION AGREEMENT AND RELEASE
2009-06-168-K10.1CONSULTING AGREEMENT
2009-03-308-K10.1DEVELOPMENT AND SUPPLY AGREEMENT
2009-01-218-K10.4IMPORTANT NOTICE ON INTEREST RATES AND PAYMENTS
2009-01-218-K10.3ADDENDUM TO CREDIT LINE AGREEMENT
2009-01-218-K10.2ADDENDUM TO CREDIT LINE ACCOUNT APPLICATION AND AGREEMENT
2009-01-218-K10.1CREDIT LINE ACCOUNT APPLICATION AND AGREEMENT

Similar stocks

Stock NameCountryMarket CapPE Ratio
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31
IMMUNIC, INC. (IMUX)United States$0.127B-1.88
Unicycive Therapeutics, Inc. (UNCY)United States$0.134B-3.70
TuHURA Biosciences, Inc./NV (HURA)United States$0.134B-4.88
INOVIO PHARMACEUTICALS, INC. (INO)United States$0.125B-1.35
Curanex Pharmaceuticals Inc (CURX)United States$0.138B
Aardvark Therapeutics, Inc. (AARD)United States$0.121B-1.80
CUMBERLAND PHARMACEUTICALS INC (CPIX)United States$0.121B-8.95
Coya Therapeutics, Inc. (COYA)United States$0.121B-6.35
Atrium Therapeutics, Inc. (RNA)United States$0.140B